Peptide Prescriber AcademyClinical Peptide Education Course & Membership →

Free · for licensed prescribers

The peptide rules change monthly. Read this month's before you prescribe.

A free monthly digest of the FDA compounding moves that actually affect your script pad: 503A bulks-list actions, PCAC dockets, 503B enforcement, and each peptide's current status. A primary source on every line.

Primary sources cited No spam Written for MD · DO · NP · PA · PharmD.
Get the tracker free, every month
Delivered the first Wednesday of each month. This month's full edition is below, no email required to read it.

Something went wrong sending that. Email hello@mail.peptideprescriberacademy.com and we'll add you by hand.

Free every month. Unsubscribe in one click. We never sell your information. Educational only, not legal or medical advice.

You're on the list.
The next edition lands the first Wednesday of the month. This month's is right below, start reading.
This month's edition · in full · free to read

Regulatory Currency Tracker

July 2026

The PCAC vote is now weeks away: on July 23–24, 2026 the FDA reviews seven peptides for the 503A bulks list, and the public-comment window is your last input before the committee decides.

Every month this digest reports what the FDA, DEA, state pharmacy boards, and major clinical bodies are saying about peptide therapy, with primary sources cited for every item. Review it before your next prescription, verify with your compounding pharmacy, and document the regulatory status in the chart note.

01The single most consequential July event

On July 23–24, 2026, the FDA's Pharmacy Compounding Advisory Committee (PCAC) meets at White Oak (with a virtual option) to recommend whether seven peptides belong on the 503A bulks list. Day 1: BPC-157, KPV, TB-500, MOTS-c. Day 2: Emideltide (DSIP), Semax, Epitalon (each as free base plus acetate). This is the first realistic path in years toward legal compounding of these peptides, which is exactly why the nuance matters.

A favorable vote is not authorization to compound. PCAC is advisory: the FDA may accept, modify, or reject its recommendation, and any addition to the bulks list requires formal rulemaking that lands months, possibly years, after July 24. Nothing about this meeting makes any of the seven legally compoundable on July 25. Plan for continued uncertainty, not a switch flipping.

Before any refill on a patient currently using one of these peptides: verify 503A status with your compounding pharmacy, document it, and counsel on possible mid-protocol supply changes.

02Three operational items this month

  1. Submit a comment before the docket closes if you want it read. Docket FDA-2025-N-6895 at regulations.gov; comments routed to committee members were prioritized through July 9, and the docket closes to written comment July 22. Speak to clinical experience with any of the seven: patient population, monitoring, observed safety. Note in the chart that current use is under active 503A review.
  2. Treat compounded GLP-1s as branded-first. The FDA's proposed determination of no clinical need would exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list; the comment period is open through July 30, 2026 (extended from June 30), with a final rule to follow. Default to FDA-approved branded GLP-1s and reserve compounded versions for documented, individualized 503A clinical-need exceptions.
  3. If you compound in California, re-read your documentation. Under the Board's "essentially a copy" rules, a compounded GLP-1 needs a patient-specific, documented clinically significant difference; adding B12 or L-carnitine alone will not clear it. Make sure each justification is patient-specific and readily retrievable.

03Per-peptide status — what changed this month

BPC-157PCAC Jul 23Under active 503A bulks-list review. Not compoundable pending FDA rulemaking.
KPVPCAC Jul 23Under active 503A bulks-list review. Not compoundable pending FDA rulemaking.
TB-500PCAC Jul 23Under active 503A bulks-list review. Not compoundable pending FDA rulemaking.
MOTS-cPCAC Jul 23Under active review. Early reporting suggests a recommendation not to add; confirm against the official record after the meeting.
DSIP · Semax · EpitalonPCAC Jul 24Day 2 of the review, same status: not compoundable pending FDA rulemaking.
Semaglutide · tirzepatide · liraglutide503B watchProposed for exclusion from the 503B bulks list; comment period open through July 30. Branded-first.
CJC-1295 · ipamorelin · thymosin α-1 · AOD-9604 · SelankUnchangedOff Category 2 since 2024-09-27; not on the bulks list. Verify with your pharmacy.

04Dates to watch

  • Jul 22, 2026PCAC docket (FDA-2025-N-6895) closes to written comment.
  • ~Jul 21, 2026FDA expected to post background and briefing materials (at least 2 business days before the meeting).
  • Jul 23–24, 2026PCAC meeting; the vote on the seven peptides.
  • Jul 30, 2026Comment period closes on the proposed 503B GLP-1 exclusion.
  • ~Feb 2027Second PCAC meeting expected (about five more peptides, names unconfirmed).
Sources for this edition (verified July 3, 2026)

FDA PCAC meeting notice — fda.gov advisory-committee calendar, "July 23–24, 2026 Meeting of the Pharmacy Compounding Advisory Committee." · PCAC docket and comment deadlines (FDA-2025-N-6895) — regulations.gov. · FDA proposed 503B GLP-1 exclusion — fda.gov press announcement plus Federal Register 2026-08552 (published May 1, 2026), with the comment-period extension in Federal Register 2026-12937 (published June 26, 2026) running the window to July 30, 2026. · California "essentially a copy" rules — 16 CCR §§ 1735.1 / 1736.1 / 1735.8 / 1736.8. · DEA fourth telemedicine flexibility extension — Federal Register 2025-24123 (through Dec 31, 2026).

This tracker reports what regulators and clinical guidance bodies are saying. It does not direct prescribing action. Each item names what changed, who it affects, where to verify, and what prescribers may want to consider with their compliance counsel. Off-label prescribing, regulatory uncertainty, and supply-chain risk are clinical decisions that belong to the prescriber and the prescriber's legal advisor. PPA provides the source material; the prescriber retains sole responsibility for clinical judgment and regulatory compliance.

Why prescribers read it

A certificate goes stale in a binder. The regulations don't wait.

01

Current, not annual

The 503A landscape shifted materially in April 2026 and moves every quarter. This tracks it monthly, so you're never prescribing off last year's rules.

02

A source on every line

FDA notices, Federal Register numbers, state board rules, docket IDs. You can verify each claim yourself and cite it in the chart.

03

Written for the script pad

No hype, no "biohacker" framing. What changed, who it affects, where to verify, and what to document, from clinicians who prescribe.

The tracker is the free front door.

Inside the Membership, the same currency feed comes with the reconstitution calculator, the 48-peptide protocol deck, the adverse-reactions reference, and a monthly clinic drop. The tools a prescriber actually reaches for chairside.

See the Membership →

Get next month's edition in your inbox.

Free, monthly, primary-source cited. Join the prescribers who read the rules before they write the script.

Subscribe free →

Educational purpose only, not medical or legal advice. The Regulatory Currency Tracker is an operational reference for licensed clinicians. It reports regulatory developments with primary sources; it does not direct prescribing. Verify the current FDA 503A status of any agent with your compounding pharmacy before each prescription. All prescribing, dosing, titration, monitoring, and discontinuation decisions belong to the licensed prescribing clinician based on the individual patient. Peptide Prescriber Academy is continuing education, not accredited CME unless separately filed with your licensing board.